Comment on "Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease".
作者信息
Pauwels Renske W M, de Vries Annemarie C, van der Woude C Janneke
机构信息
Erasmus University Medical Center, Rotterdam, the Netherlands.
出版信息
Inflamm Bowel Dis. 2019 Apr 11;25(5):e59. doi: 10.1093/ibd/izy273.
PMID:31222304
Abstract
摘要
相似文献
1
Comment on "Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease".
Inflamm Bowel Dis. 2019 Apr 11;25(5):e59. doi: 10.1093/ibd/izy273.
2
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.
Rheumatology (Oxford). 2019 Jun 1;58(6):1113-1115. doi: 10.1093/rheumatology/kez056.
3
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease: reply.
Rheumatology (Oxford). 2019 Jun 1;58(6):1115-1117. doi: 10.1093/rheumatology/kez053.
4
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab.
Drug Des Devel Ther. 2014 Dec 17;9:147-54. doi: 10.2147/DDDT.S50348. eCollection 2015.
5
Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
J Med Econ. 2018 Nov;21(11):1102-1109. doi: 10.1080/13696998.2018.1511568. Epub 2018 Sep 3.
6
Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases.
Dig Dis Sci. 2018 Sep;63(9):2168-2171. doi: 10.1007/s10620-018-5039-y.
7
Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects.
Dig Liver Dis. 2016 Nov;48(11):1391-1393. doi: 10.1016/j.dld.2016.08.122. Epub 2016 Sep 1.
8
Response to 'Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire?'.
J Crohns Colitis. 2017 May 1;11(5):644-645. doi: 10.1093/ecco-jcc/jjw202.
9
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Gut. 2019 Jan;68(1):25-39. doi: 10.1136/gutjnl-2018-316023. Epub 2018 May 5.
10
Vedolizumab (Entyvio) for inflammatory bowel disease.
Med Lett Drugs Ther. 2014 Sep 15;56(1451):86-8.
引用本文的文献
1
Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice.
J Gastroenterol Hepatol. 2020 Nov;35(11):1893-1901. doi: 10.1111/jgh.15063. Epub 2020 May 4.
Zotero 插件